Industry
Biotechnology
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Loading...
Open
4.40
Mkt cap
6.4M
Volume
103K
High
4.43
P/E Ratio
-1.35
52-wk high
5.20
Low
4.00
Div yield
N/A
52-wk low
2.78
Portfolio Pulse from
November 12, 2024 | 2:15 pm
Portfolio Pulse from
November 07, 2024 | 2:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 12:48 pm
Portfolio Pulse from Benzinga Insights
September 30, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 11:00 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 1:41 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 12:48 pm
Portfolio Pulse from Benzinga Newsdesk
March 25, 2024 | 10:59 am
Portfolio Pulse from Happy Mohamed
March 22, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
January 17, 2024 | 2:05 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.